Healthcare ETFs Rise as Moderna Shares Nearly Double on Melanoma Trial Success
On Wednesday, healthcare-focused exchange-traded funds saw gains following a nearly 100% surge in shares of Moderna. The jump was driven by positive late-stage trial results for Intismeran Autogene, an mRNA-based cancer therapy developed jointly with Merck. This experimental treatment showed promising outcomes for melanoma patients. The strong performance of Moderna's stock had a ripple effect on broader healthcare ETFs as investors reacted positively to the clinical progress in oncology and mRNA technology applications beyond vaccines. The development is seen as a significant milestone for both companies, highlighting continued innovation in cancer immunotherapy using mRNA platforms.
Topics: Biotechnology Clinical Trials ETFs Healthcare